An official website of the United States government
Publication Information
Affiliation
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Ave., St. Louis, MO 63110, USA. dibiscam@slu.edu
Authors
Bacon B, Banner BF, Bell MC, Bhan AK, Bonkovsky HL, Brunt EM, Chen FY, Chung M, Chung RT, Contos MJ, Cormier M, Craig JR, Crowder N, Curto TM, Davis GL, DeSanto J, Di Bisceglie AM, Dienstag JL, Elbein R, Everhart JE, Everson GT, Fontana RJ, Garcia-Tsao G, Ghany MG, Giansiracusa D, Goodman ZD, Govindarajan S, Greenson JK, Gretch DR, HALT-C Trial Investigators, Haynes-Williams V, Hoefs JC, Hofmann C, Hoofnagle JH, Jamal MM, Jones CB, Kelley M, King D, Kleiner D, Kugelmas M, Kutner M, Lee WM, Lemon SM, Liang TJ, Lindsay KL, Lok AS, Malet PF, Massey LJ, McKinley C, Mihova MS, Mills AS, Milstein SL, Molchen WA, Morgan TR, Morishima C, Naishadham D, Nash SR, Neuschwander-Tetri B, Padmanabhan L, Park C, Park Y, Perrillo RP, Reid AE, Richtmyer PA, Rivera E, Robuck PR, Rogers TE, Seeff LB, Shankar R, Sheik M, Shelton J, Shiffman ML, Smith P, Snow KK, Sterling RK, Stoddard AM, Szabo G, Tran D, Wright EC
Studies
Citation
Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL, HALT-C Trial Investigators. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008 Dec 4;359(23):2429-41.Abstract
In patients with chronic hepatitis C who do not have a response to antiviral treatment, the disease may progress to cirrhosis, liver failure, hepatocellular carcinoma, and death. Whether long-term antiviral therapy can prevent progressive liver disease in such patients remains uncertain.